Edward Ball

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Ball’s research focuses on the development of monoclonal antibody (mAb)-targeted immunotherapy and its translation to the treatment of patients with malignancy. His lab produced mAbs to myeloid-associated antigens expressed on myeloid leukemia cells. These antibodies have been used clinically for the diagnosis and treatment of acute myeloid leukemia (AML).He has conducted multi-center clinical trials using antibody-mediated purging using the AML cells from the marrow of patients with leukemia prior to transplantation, after high dose chemotherapy. He has also developed in vivo therapeutics using an anti-CD15 mAb and a bispecific antibody. This bispecific antibody (251xH22) mediates antibody–directed cellular cytotoxicity(ADCC) of AML cells mediated by normal leukocyte cells including natural killer cells, monocytes and granulocytes. They determined that there are direct signals transduced by binding of the anti-CD33 monoclonal antibody that lead to death of AML cells mediated in part by the protein kinase Syk. This led to an investigator-initiated multi-center Phase I/II clinical trial combining 5-azacytidine (that increases Syk expression) and the anti-CD33 monoclonal antibody Mylotarg. His laboratory has also been working the generation of cytotoxic T cells in vitro in a novel culture system. Based on this pre-clinical work, they developed a clinical trial wherein patients with AML undergoing autologous stem cell transplantation are administered autologous cytotoxic T cells following the transplant with the goal of reducing the relapse rate. Dr. Ball is principal investigator on numerous clinical trials active at UCSD Medical Center ranging from Phase I investigator-initiated to Phase III trials. He has been a recipient of a NCI and NHLBI-sponsored UO1 grant from the NIH. He recently completed a study of a novel treatment of relapse following allogeneic stem cell transplantation. The infusion of a monoclonal antibody directed to the cytotoxic T lymphocyte antigen-4 (CTLA-4) was tested in series of patients with relapse for safety and efficacy. The study demonstrated the safety of this approach and some promising signs of efficacy. Dr. Ball has been the elected Secretary of the American Society of Blood and Marrow Transplantation and a member of the steering committee of the BMT Clinical Trials Network.

    Education and Training
    BS - Biochemistry, University of Maryland - 1968-1972
    MD - Case Western Reserve University - 1972-1976
    Resident - Hartford Hospital - 1976-1979
    Fellow - Hematology & Oncolog, University Hospitals of Cleveland - 1979-1981
    Fellow - Hematology & Oncology, Dartmouth- Hitchcock Medical Center - 1982-1983

    Collapse Research 
    Collapse Research Activities and Funding
    Adoptive T-Cell Therapy for Acute Leukemia
    NIH R21CA132277Jan 1, 2010 - Dec 31, 2012
    Role: Principal Investigator
    Symposium- Advances in Stem Cell Transplantation
    NIH R13CA102080May 2, 2003 - Apr 30, 2004
    Role: Principal Investigator
    CTLA-4 Blockade in Allo Stem Cell Transplantation
    NIH R01CA093891Sep 30, 2002 - Aug 31, 2008
    Role: Principal Investigator
    CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor
    NIH U01HL069273Sep 30, 2001 - Jul 31, 2013
    Role: Principal Investigator
    TARGETED CELLULAR TOXICITY OF SCCL CELLS
    NIH R03CA072657Sep 30, 1997 - Aug 31, 2000
    Role: Principal Investigator
    MONOCLONAL ANTIBODIES/SMALL CELL CARCINOMA OF THE LUNG
    NIH R01CA037868Sep 30, 1985 - May 31, 1995
    Role: Principal Investigator
    Monoclonal Antibody for Treatment of Leukemia
    NIH R01CA031888Jun 1, 1983 - Jun 30, 2006
    Role: Principal Investigator
    MONOCLONAL ANTIBODIES REACTIVE WITH HUMAN LEUKEMIA CELLS
    NIH R23CA031888Jun 1, 1983 - May 31, 1986
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR. Exp Hematol Oncol. 2021 Feb 02; 10(1):8. Johnson DT, Davis AG, Zhou JH, Ball ED, Zhang DE. PMID: 33531067.
      View in: PubMed   Mentions:
    2. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clin Med Insights Oncol. 2020; 14:1179554920976366. Jeong AR, Ball ED, Goodman AM. PMID: 33447123.
      View in: PubMed   Mentions:
    3. In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. Cytotherapy. 2021 Apr; 23(4):320-328. Ferrari V, Tarke A, Fields H, Ferrari L, Conley T, Ferrari F, Kosaloglu-Yalçin Z, Sette A, Peters B, McCarthy CL, Bashey A, Tzachanis D, Ball ED, Tanaka TN, Bejar R, Lane TA, Vitiello A. PMID: 33262074.
      View in: PubMed   Mentions:    Fields:    
    4. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2021 Jul; 21(7):849-862. Goldenson BH, Goodman AM, Ball ED. PMID: 32990476.
      View in: PubMed   Mentions: 1     Fields:    
    5. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191. Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. PMID: 32478814.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    6. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    7. Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):431-437.e2. Klebaner D, Koura D, Tzachanis D, Ball ED, Horwitz S, Goodman AM. PMID: 32284297.
      View in: PubMed   Mentions:    Fields:    
    8. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 2019 05; 25(5):955-964. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE. PMID: 30605731.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biol Blood Marrow Transplant. 2019 04; 25(4):699-711. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL. PMID: 30423480.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    10. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019 04; 104(4):844-854. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE. PMID: 30381298.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    11. Improved accuracy of clinical HLA genotyping by next-generation DNA sequencing affects unrelated donor search results for hematopoietic stem cell transplantation. Hum Immunol. 2018 Dec; 79(12):848-854. Allen ES, Yang B, Garrett J, Ball ED, Maiers M, Morris GP. PMID: 30316972.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):346-352.e5. Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED. PMID: 29572158.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    13. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2018 09; 182(6):916-920. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. PMID: 28771676.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    14. Proinflammatory Dual Receptor T Cells in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1852-1860. Balakrishnan A, Gloude N, Sasik R, Ball ED, Morris GP. PMID: 28750779.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. What are the latest advancements in acute myeloid leukemia therapy? Future Oncol. 2017 Apr; 13(10):867-871. Goodman A, Ball ED. PMID: 28266249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis. Oncology (Williston Park). 2017 02 15; 31(2):122-4, 126-8. Goodman AM, Rust M, Costello C, Ball ED. PMID: 28205192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant. 2017 Apr; 23(4):625-634. Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD. PMID: 28104514.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    18. CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell. 2016 Nov 14; 30(5):792-805. Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T. PMID: 27908736.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    19. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 11 03; 19(5):599-612. Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM. PMID: 27570067.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    20. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia and Lymphoma Society Blood Cancer Research Partnership . PMID: 27410923.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCellsCTClinical Trials
    21. Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia. Br J Haematol. 2016 Mar; 172(6):987-90. Wang HY, McMahon C, Ali SM, Young LE, Yekezare S, Ross JS, Ball ED. PMID: 26147192.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemia. J Comput Biol. 2015 Apr; 22(4):266-88. Ong E, Szedlak A, Kang Y, Smith P, Smith N, McBride M, Finlay D, Vuori K, Mason J, Ball ED, Piermarocchi C, Paternostro G. PMID: 25844667.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    23. Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists. Cancer Immunol Immunother. 2015 Jun; 64(6):737-44. Zhong R, Li H, Messer K, Lane TA, Zhou J, Ball ED. PMID: 25795133.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    24. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants. Transfusion. 2014 Jul; 54(7):1857-63. Cunard R, Marquez II, Ball ED, Nelson CL, Corringham S, Clopton P, Sanchez AP, Lane T, Ward DM. PMID: 24372185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. A case of interdigitating dendritic cell sarcoma/histiocytic sarcoma--a diagnostic pitfall. Int J Clin Exp Pathol. 2014; 7(1):378-85. Johnson RL, Boisot S, Ball ED, Wang HY. PMID: 24427360.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20; 31(33):4199-206. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. PMID: 24127452.
      View in: PubMed   Mentions: 181     Fields:    Translation:HumansCTClinical Trials
    27. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8. Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH. PMID: 22766223.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    28. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. Pharmacotherapy. 2012 Jul; 32(7):596-603. Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED. PMID: 22760691.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J Med Chem. 2012 Jan 26; 55(2):725-34. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G. PMID: 22221201.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    30. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ. PMID: 21810400.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    31. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Feb; 18(2):257-64. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED. PMID: 21736867.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    32. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15; 118(2):418-27. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. PMID: 21717444.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    33. Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Support Care Cancer. 2011 Dec; 19(12):2015-20. Dimsdale JE, Ball ED, Carrier E, Wallace M, Holman P, Mulroney C, Shaikh F, Natarajan L. PMID: 21116652.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Chut T, Soiffer R, Mitrovich RC, Lowy I, Ball ED. PMID: 20713164.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    35. Monoclonal antibodies in the treatment of hematologic malignancy. Best Pract Res Clin Haematol. 2010 Sep; 23(3):403-16. Ball ED, Broome HE. PMID: 21112039.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    36. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol Blood Marrow Transplant. 2011 Apr; 17(4):566-73. Espinosa-Aguilar L, Green JS, Forrest GN, Ball ED, Maziarz RT, Strasfeld L, Taplitz RA. PMID: 20708084.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic Health
    37. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant. 2011 Apr; 17(4):558-65. Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. PMID: 20674758.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    38. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials. Stat Med. 2010 Mar 30; 29(7-8):712-20. Messer K, Natarajan L, Ball ED, Lane TA. PMID: 20213706.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    39. Increasing the punch of reduced-intensity transplants. Blood. 2009 Dec 24; 114(27):5410-1. Ball ED. PMID: 20035041.
      View in: PubMed   Mentions:    Fields:    
    40. Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2011 Jun; 17(2):85-90. Trivedi M, Martinez S, Corringham S, Medley K, Ball ED. PMID: 20015929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Oct; 15(10):1306-13. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED. PMID: 19747639.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581-8. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED. PMID: 18974373.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    43. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Exp Hematol. 2008 Apr; 36(4):486-94. Zhong RK, Lane TA, Ball ED. PMID: 18249062.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    44. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion. 2007 Nov; 47(11):2153-60. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA. PMID: 17958545.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    45. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol. 2007 Jan; 136(2):237-48. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Maciejewski JP. PMID: 17156396.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    46. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol. 2006 Jun; 34(6):728-35. Nguyen DH, Ball ED, Varki A. PMID: 16728277.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    47. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2224-31. Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED. PMID: 16609038.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    48. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leuk Res. 2006 Apr; 30(4):503-6. Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED. PMID: 16303178.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    49. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb; 33(2):199-211. Balaian L, Ball ED. PMID: 15676214.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    50. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs. 2004 Nov; 15(10):921-7. Zhou J, Chen J, Mokotoff M, Ball ED. PMID: 15514561.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    51. Summary of the 12th international symposium on recent advances in stem cell transplantation. Exp Hematol. 2004 Oct; 32(10):881-4. Ball ED, Ho AD. PMID: 15504542.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    52. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res. 2004 Aug; 28(8):821-9. Balaian L, Ball ED. PMID: 15203280.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    53. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol. 2004 May; 32(5):470-5. Zhong R, Law P, Wong D, Merzouk A, Salari H, Ball ED. PMID: 15145215.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    54. Update in hematology. Ann Intern Med. 2003 Dec 02; 139(11):916-22. Ball ED. PMID: 14644894.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    55. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4953-60. Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD, Ball ED. PMID: 14581370.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    56. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol. 2003 May; 31(5):363-71. Balaian L, Zhong RK, Ball ED. PMID: 12763134.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    57. Development of allogeneic hematopoietic stem cell transplantation (HSCT). Cancer Treat Res. 2002; 110:1-37. Castro JE, Ball ED. PMID: 11908193.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    58. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. PMID: 12434951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    59. Reversal of Graft-Versus-Host Disease with Infusion of Stored Autologous Bone Marrow Cells Following Combined Liver-Bone Marrow Allotransplantation in Man. Transplant Sci. 1993 Apr; 3(1):76-77. Ricordi C, Tzakis AG, Demetris AJ, Zeevi A, Rybka WB, Nalesnik MA, Ukah FO, Fontes PA, Ball ED, Starzl TE. PMID: 21572946.
      View in: PubMed   Mentions: 2     Fields:    
    Edward's Networks
    Concepts (340)
    Derived automatically from this person's publications.
    _
    Co-Authors (44)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _